STOCK TITAN
  1. Home
  2. News
  3. OCGN

Ocugen Inc - OCGN STOCK NEWS

Welcome to our dedicated news page for Ocugen (Ticker: OCGN), a resource for investors and traders seeking the latest updates and insights on Ocugen.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Ocugen's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Ocugen's position in the market.

News
Ocugen CSO to Participate in 4th Annual Gene Therapy for Ophthalmic Disorders Conference
Rhea-AI Summary
Ocugen's Chief Scientific Officer, Arun Upadhyay, will be speaking at the 4th Annual Gene Therapy for Ophthalmic Disorders conference in Boston. He will discuss endpoints for gene therapy clinical trials and the design of first-in-human clinical studies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.23%
Tags
conferences
-
News
Ocugen to Participate in Fireside Chat at Chardan’s 7th Annual Genetic Medicines Conference
Rhea-AI Summary
Ocugen to participate in fireside chat at Chardan 7th Annual Genetic Medicines Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.49%
Tags
conferences
-
News
Ocugen, Inc. Announces Connie Collingsworth Joins Business Advisory Board
Rhea-AI Summary
Connie Collingsworth, former COO of the Bill and Melinda Gates Foundation, joins Ocugen's Business Advisory Board (BAB) to drive partnerships and access to therapies worldwide. Her financial background will support new business development opportunities. Collingsworth's expertise and global connections may strengthen Ocugen's position in the market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.01%
Tags
management
News
Ocugen to Participate in Panel at Cantor Fitzgerald Global Healthcare Conference 2023
Rhea-AI Summary
Ocugen CEO to participate in Cantor Fitzgerald Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.49%
Tags
conferences
-
News
Ocugen Announces Positive Clinical Study Update from the Phase 1/2 Trial of OCU400, a Modifier Gene Therapy Product Candidate, for the Treatment of Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA)
Rhea-AI Summary
Positive safety and efficacy trends observed in the clinical study update for OCU400 investigational drug product in RP and LCA subjects. 83% of subjects demonstrated stabilization or improvement in treated eye either on BCVA or LLVA or MLMT scores from baseline. Notably, 86% of RHO mutation subjects experienced either stabilization of or increase in MLMT scores from baseline including a subset of 29% that demonstrated a 3 Lux luminance level improvement. OCU400 has the potential to be a gene-agnostic therapeutic for RP and LCA patients with inherited retinal degeneration. No serious adverse events were reported in the low and medium-dose cohorts.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.29%
Tags
clinical trial
-
News
Ocugen to Host Virtual Investor & Analyst Event on September 13, 2023
Rhea-AI Summary
Ocugen to share updated results from Phase 1/2 trial of OCU400 for Retinitis Pigmentosa and Leber Congenital Amaurosis. Investor and Analyst Event on Sept 13. Webcast and conference call details provided.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.29%
Tags
conferences
News
Ocugen Provides Business Update with Second Quarter 2023 Financial Results
Rhea-AI Summary
Ocugen reports Q2 2023 financial results and provides business update, plans to initiate Phase 1/2 trials for OCU410 and OCU410ST gene therapies by end of 2023, plans to share updated data on OCU400 this quarter, and continues discussions for government support of its inhaled vaccines.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.03%
Tags
earnings
-
News
Ocugen to Host Conference Call on Tuesday, August 22 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2023 Financial Results
Rhea-AI Summary
Ocugen to host conference call and webcast to discuss Q2 2023 financial results and business update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
-
News
Ocugen CEO & CSO to Present at 41st Annual AAPI Convention and Scientific Assembly
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.63%
Tags
conferences
News
Ocugen, Inc. Announces Adjournment of Annual Meeting of Shareholders
Rhea-AI Summary
Ocugen's 2023 Annual Meeting of Shareholders adjourned due to lack of required quorum. The meeting will resume on June 23, 2023, virtually. Shareholders who have already submitted a proxy do not need to vote again.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Stock OCGN logo
Ocugen Inc

Nasdaq:OCGN

OCGN Rankings

#3335 Ranked by Market Cap
#5296 Ranked by Stock Gains
N/A Ranked by Dividends

OCGN Stock Data

438.79M
252.38M
1.45%
10.33%
16.95%
Sanitary Paper Product Manufacturing
Manufacturing
Link
US
Malvern

About OCGN

ocugen, inc., is a rapidly growing ophthalmology company developing a rich clinical pipeline of innovative therapies that address rare and underserved ocular disorders. the company’s lead programs in ocular graft versus host disease (ocu300) and chronic dry eye disease (ocu310) are expected to enter pivotal clinical trials in 2018. ocu300 received the first and only orphan drug designation for ocular graft versus host disease, providing certain regulatory and economic benefits. ocugen is also developing novel biologic therapies for retinitis pigmentosa (ocu100) and wet amd (ocu200), as well as a groundbreaking modifier gene therapy platform with potential to address a broad spectrum of inherited retinal disorders (ocu400). for more information, please visit www.ocugen.com.